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Abstract
Gastric cancer is the second most common cause of cancer-related mortality worldwide.
Accurate prediction of disease progression is difficult, and new biomarkers for clinical use
are essential. Recently, we reported that the proteasome-associated deubiquitinating
enzyme UCHL5/Uch37 is a new prognostic marker in both rectal cancer and pancreatic duc-
tal adenocarcinoma. Here, we have assessed by immunohistochemistry UCHL5 tumor
expression in gastric cancer. The study cohort comprised 650 patients, who underwent sur-
gery in Helsinki University Hospital, Finland, between 1983 and 2009. We investigated the
association of cytoplasmic UCHL5 tumor expression to assess clinicopathological parame-
ters and patient survival. Positive cytoplasmic UCHL5 tumor immunoexpression is linked to
increased survival of patients with small (<5 cm) tumors (p = 0.001), disease stages I-II (p =
0.025), and age 66 years or older (p = 0.037). UCHL5 is thus a potential marker in gastric
cancer with new prognostic relevance.
Introduction
Gastric cancer is an aggressive disease, with a 5-year survival rate in the Western world of less
than 30%, despite improvements in surgical and oncological treatments [1,2]. As the path of
the disease varies, and current TNM staging is insufficient in accurately predicting patient sur-
vival, new tumor biomarkers for clinical use are vital. We have recently demonstrated that
patients with high tumor immunoexpression of the deubiquitinating enzyme UCHL5/Uch37
had better prognosis in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma
(PDAC) [3,4].
Modulators of the ubiquitin-proteasome system (UPS) have recently emerged as attractive
targets in cancer therapy [5,6]. The majority of controlled protein degradation is mediated by
UPS, which is a critical part of maintaining proteostasis. Proteasome substrates are degraded
after their polyubiquitination by E1 to E3 enzymes [7]. Important players include also
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deubiquitinating enzymes (DUBs) removing ubiquitin(s) from target proteins. Approximately
90 DUBs exist in the human genome, around 40 of which have been linked to cancer [8,9].
Three DUBs associate with the proteasome, including UCHL5/Uch37, a cysteine protease of
the family of ubiquitin C-terminal hydrolases (UCHs). The DUB activity of UCHL5 is induced
by its reversible and evolutionarily conserved binding to the Admr1/Rpn13 subunit of the 26S
proteasome [10,11]. In addition, DUB-inactive UCHL5 associates with the NRFKB subunit of
the INO80 chromatin remodeling complex, but the physiological significance of this associa-
tion is unknown [12,13]. The C. elegans homolog of UCHL5, UBH-4, tissue-specifically modu-
lates proteasome activity, also affecting the health and lifespan of these animals [11]. UCHL5
function is essential, as UCHL5 knockout in mice is embryonically lethal [14].
In cancer and healthy tissues both the expression level and subcellular location of UCHL5
vary greatly [15]. In esophageal squamous cell carcinoma, hepatocellular carcinoma, and epi-
thelial ovarian cancer, high UCHL5 expression correlated with cancer recurrence and reduced
patient survival [16–18]. We recently demonstrated that patients with high UCHL5 nuclear
positivity in PDAC, and strong positive UCHL5 expression in lymph-node-positive (Dukes C/
stage III) rectal cancer, showed a more favorable prognosis [3,4]. Here, we have investigated
the potential prognostic role of UCHL5 in gastric cancer.
Materials and methods
Patients
Samples for this study came from patients treated for gastric cancer at the Department of
Surgery, Helsinki University Hospital, Finland, between 1983 and 2009. The study cohort
comprised 650 patients, who underwent total or partial gastrectomy with D1- or D2-lym-
phadenectomy; 371 (57.1%) of them with curative intent. Their median age at the time of
surgery was 66.9 (interquartile range 57.0–75.0), and 335 (51.5%) were women. Median fol-
low-up time was 1.6 (interquartile range 0.6–4.7) years. Clinical data came from patient rec-
ords, and survival data from the Population Register Centre of Finland; cause of death was
provided by Statistics Finland [19,20]. The study was approved by the Surgical Ethics Com-
mittee of Helsinki University Hospital (Dnro HUS 226/E6/ 06, extension TMK02 §66
17.4.2013), and the National Supervisory Authority of Welfare and Health gave permission
to use the tissue samples without individual consent in this retrospective study (Valvira
Dnro 10041/06.01.03.01/2012).
Preparation of tumor tissue microarrays and immunohistochemistry
The surgical tissue samples provided by the Department of Pathology, Helsinki University
Hospital, were formalin-fixed and paraffin-embedded. The patient tissues were de-identified
and analyzed anonymously. All histological slides were re-evaluated by an experienced pathol-
ogist, who defined and marked areas representing the highest grade of an individual tumor.
For the preparation of tissue microarray blocks (TMA), representative areas of tumor speci-
mens were defined and marked on hematoxylin- and eosin-stained slides. A semiautomatic
tissue microarrayer (Tissue Arrayer 1, Beecher Instruments Inc., Silver Spring, MD, USA) was
used to take three 0.6 mm (1983–1999) or four 1.0 mm (2000–2009) cores from each tumor
block, which were then cut into 4-μm sections. Deparaffinization of the slides was done in
xylene, and rehydration in a gradually decreasing concentration of ethanol in distilled water.
Antigen retrieval was done with a PreTreatment module (Lab Vision Corp., Fremont, CA,
USA) in Tris-HCl (pH 8.5) buffer for 20 min. at 98˚C. Autostainer 480 (Lab Vision Corp., Fre-
mont, CA, USA) by the Dako REAL EnVision Detection system, Peroxidase/DAB+, Rabbit/
Mouse (Dako, Glostrup, Denmark) served for staining of the sections. A rabbit polyclonal
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anti-UCHL5 antibody (Sigma Aldrich, MO, USA, HPA005908; diluted to 1:800 = 8 μg/ml)
was used for one hour at room temperature for tissue incubation. Staining was validated by a
similar protocol with a mouse monoclonal anti-UCHL5 antibody (Santa Cruz, TX, USA, sc-
271002; diluted to 1:1000) in a subset of 98 samples.
Evaluation of stainings
UCHL5 cytoplasmic staining was scored according to its intensity as either negative (0), weak
positive (1), moderate positive (2), or strong positive (3). The stainings were evaluated first by
one investigator (A.L. or L.A.), and then by J.H., independently of any knowledge of clinical
data or patient outcome. Possible disagreements with sample scores were discussed until una-
nimity. Representative images for each staining intensity were chosen at random and image
brightness was adjusted equally for all images by Adobe Photoshop.
Statistical analysis
UCHL5 immunoexpression was dichotomized into either negative (score 0) or positive (scores
1–3), and the maximum score for each sample served for statistical analysis. Fisher’s exact test
and linear-by-linear association test served to evaluate any association between UCHL5
expression and clinicopathological variables. Cancer-specific survival (CSS) was calculated
from date of surgery to date of death from gastric cancer or until end of follow-up. The
Kaplan-Meier method was used for survival analysis, and the log rank-test for comparing the
different groups. Exact 95% confidence intervals (CI) were calculated for survival rates. As the
median age of patients in the first series (operated 1983–1999) was 66, patients were divided
into groups: younger than 66, or 66 and over. Uni- and multivariable survival analysis, used
the Cox regression proportional hazard model, and the multivariable model was adjusted for
age, gender, stage, and tumor size ( 5 cm vs. <5 cm). The Cox model assumption of constant
hazard ratios over time was tested. A time-dependent covariate was included separately for
each testable variable at a time. All variables fulfilled the assumption, except in one multivari-
able model (see Results). Interaction terms were considered. A p value less than 0.05 was con-
sidered significant, with all tests two-sided. Statistical analyses were performed with SPSS
version 24.0 (IBM SPSS Statistics, version 24.0; SPSS, Inc., Chicago, IL, USA, an IBM Com-
pany), and with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Immunohistochemical staining and association of UCHL5
immunoexpression with clinicopathological parameters
UCHL5 immunoexpression was evaluable in 490 (75.4%) of the tumor specimens. A cyto-
plasmic and nuclear UCHL5 staining pattern was observable when present throughout the
tumor tissue, and was of uniform intensity. Cytoplasmic UCHL5 expression was negative in
111 (22.7%), weak in 217 (44.3%), moderate in 119 (24.3%), and strongly positive in 43 (8.8%)
samples. UCHL5-positive cytoplasmic immunoexpression occurred in 379 (77.3%) samples.
Due to overlapping cytoplasmic and nuclear staining in a large number of samples, separate
evaluation of nuclear staining was not possible. Staining of a subset of samples with a different
anti-UCHL5 antibody displayed similar UCHL5 immunoexpression pattern (data not shown).
Tumor-adjacent normal-appearing tissue exhibited, for the most part, low staining. Represen-
tative images for all intensities (0–3) are depicted in Fig 1. Positive UCHL5 immunoexpression
associated with intestinal cancer type (p = 0.004), but not with any of the other clinicopatho-
logical variables (Table 1).
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Survival analysis
Positive UCHL5 immunoexpression (staining scores 1–3) was compared to negative immu-
noexpression (staining score 0) in the entire patient cohort (Fig 2A). More detailed analysis
revealed that patients with positive UCHL5 expression exhibited better survival than those
with negative expression in the subgroups of patients with stages I-II of the disease (p = 0.025,
Fig 2B), those with small (<5 cm) tumor size (p = 0.001, Fig 2C), and in patients age 66 or
older (p = 0.037, Fig 2D).
The 5-year cancer-specific survival (CSS) of stages I-II gastric cancer was 77.2% (95% CI
69.2–83.4) in patients with positive UCHL5 immunoexpression, compared to 59.0% (95% CI
41.3–73.0) in patients with negative UCHL5 immunoexpression. In the subgroup of patients
with small (<5 cm) tumors, 5-year CSS was 71.4% (95% CI 62.3–78.6) for UCHL5-positive
patients and 45.5% (95% CI 30.0–59.7) for those UCHL5-negative. Patients 66 or older with
positive UCHL5 immunoexpression displayed a 5-year CSS of 31.8% (95% CI 24.9–38.9), com-
pared to 22.0% (95% CI 11.8–34.2) for negative UCHL5 immunoexpression (Table 2).
In univariable Cox-regression analysis, positive UCHL5 expression was not a significant
prognostic factor (HR = 0.81; 95% CI 0.63–1.05; p = 0.108, Table 3). UCHL5 expression did
not fulfill the Cox assumption of proportional hazard ratios over time with all patients
included for a multivariable model. However, positive UCHL5 expression was a significant
prognostic factor in both uni- and multivariable analysis in subgroups of patients with disease
stages I-II (p = 0.028 and p = 0.001, respectively; S1 Table), and in patients with small (<5 cm)
tumor size (p = 0.001 and p<0.001, respectively; S2 Table).
Discussion
Here, we demonstrate, to our knowledge for the first time, that in certain subgroups of gas-
tric cancer patients, UCHL5 immunoexpression in tumor tissue is linked to increased sur-
vival. In stages I-II of the disease, small (<5 cm) tumor size, or age 66 or older, UCHL5
Fig 1. Representative images of UCHL5 staining in gastric cancer. Tumors with A) negative (0), B) weak positive
(1), C) moderate positive (2), and D) strong positive (3) staining. Original magnification 40x.
https://doi.org/10.1371/journal.pone.0193125.g001
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positivity was linked to better prognosis, when compared to patients with negative tumor
immunoexpression.
Most gastric cancer samples, according to the Human Protein Atlas, display predominantly
moderate to low UCHL5 immunoreactivity [15]. Similarly, moderate to low expression com-
prised approximately 69% of our cases. Previously, high UCHL5 expression has been linked to
poor prognosis or cancer recurrence in esophageal squamous cell carcinoma, epithelial ovarian
cancer, and in hepatocellular carcinoma [16–18]. Contrary to these findings, we here demon-
strate that positive UCHL5 immunoexpression is a predictor for better survival in certain sub-
groups of gastric cancer patients. We have recently shown corresponding results in PDAC,
Table 1. Association of UCHL5 with clinicopathological variables in gastric cancer patients.
UCHL5
Negative Positive
n (%) 111 (22.7) 379 (77.3) p value
Age, years
<66 51 (22.0) 181 (78.0) 0.747
66 60 (23.3) 198 (76.7)
Gender
Male 54 (22.3) 188 (77.7) 0.914
Female 57 (23.0) 191 (77.0)
TNM stage
IA-IB 21 (20.8) 80 (79.2) 0.619
II 19 (21.3) 70 (78.7)
IIIA-IIIC 41 (24.6) 126 (75.4)
IV 30 (22.7) 102 (77.3)
Unavailable data 1
pT-classification
pT1 16 (22.5) 55 (77.5) 0.560
pT2 16 (21.9) 57 (78.1)
pT3 39 (20.4) 152 (79.6)
pT4 40 (25.8) 115 (74.2)
pN-classification
pN0 35 (20.5) 136 (79.5) 0.567
pN+ 71 (22.9) 239 (77.1)
Unavailable data 5 4
pM-classification
pM0 83 (22.9) 279 (77.1) 0.902
pM1 28 (21.9) 100 (78.1)
Laure´n classification
Intestinal 34 (16.3) 175 (83.7) 0.004
Diffuse 75 (27.5) 198 (72.5)
Unavailable data 2 6
Tumor size, cm
<5 46 (26.0) 131 (74.0) 0.173
5 61 (20.3) 240 (79.7)
Unavailable data 4 8
Abbreviations: UCHL5 = ubiquitin C-terminal hydrolase L5; Unavailable data: number of patients lacking the
subgroup characteristic.
https://doi.org/10.1371/journal.pone.0193125.t001
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where positive nuclear or high cytoplasmic UCHL5 expression predicts better survival [4].
Additionally, patients with high cytoplasmic UCHL5 immunoreactivity had increased survival
in lymph node-positive (Dukes C/stage III) rectal cancer [3].
Proteasome-associated UCHL5 is a negative regulator of proteasome activity, as established
in both human cancer cell-lines and the nematode C. elegans [11,12,21]. It is possible that
excess UCHL5 expression substantially impairs proteasome activity, causing abnormal accu-
mulation of proteasomal substrates, and harming tumor cells. Interestingly, patients with high
UCHL5 expression have better prognosis in later stages of both pancreatic and rectal cancer
[3,4], whereas a similar survival benefit was linked to lower stages (stages I-II) of gastric cancer.
This may reflect the tissue-specificity that UCHL5 displays both in its expression and in its
role in normal cell functions [11]. A decline in proteostasis is one of the hallmarks of aging
[22]. For elderly patients with reduced proteostasis capacity, high UCHL5 levels may further
inhibit proteasome activity, thereby promoting apoptosis in cancer cells. Alternatively, the lon-
ger survival of UCHL5 may be proteasome independent, and conveyed via chromatin remod-
eling by the UCHL5 interacting partner INO80 [12,13]. However, the strong cytoplasmic
Fig 2. Gastric cancer-specific survival presented by the Kaplan-Meier method. Negative (no staining) versus positive (weak,
moderate, and strong positive staining) UCHL5 immunoexpression was compared in A) the whole patient cohort, B) patients with
stages I-II of the disease, C) patients with small (<5 cm) tumor size, and D) patients 66 or older. The log rank-test was used for
calculating the p value.
https://doi.org/10.1371/journal.pone.0193125.g002
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expression pattern of UCHL5 does not support a predominantly chromatin remodeling-
dependent effect. Further studies are important to discern UCHL5 molecular mechanisms in
normal healthy tissues, as well as in different disease conditions.
Today, proteasome inhibitors are in routine clinical use for treatment of such diseases as
multiple myeloma [23,24] and mantle cell lymphoma [25], albeit with dose-dependent toxici-
ties, a limited therapeutic window, and substantial drug resistance [26]. Thus, there exists
growing interest in therapeutically targeting other components of the UPS, including different
DUBs [5,6]. Concurrent pharmacological inhibition of the proteasome-associated DUBs
USP14 and UCHL5 reduces proliferation [5,27], and increases survival in multiple myeloma
xenograft models [28]. Modulating proteasome activity by targeting one or several of the pro-
teasome-associated DUBs may provide an effective therapeutic option.
Despite recent advances in surgical and oncological therapies, the general prognosis in gas-
tric cancer is poor. Choosing the correct treatment options for individual patients, both before
and after possible surgery, may have far-reaching consequences. However, still only a few
prognostic markers are in clinical use. The specificity and sensitivity of currently available
markers are insufficient for use in diagnosis of gastric cancer. Thus far, reports on CEA or CA
Table 2. Kaplan-Meier analysis for cancer-specific survival stratified by subgroups of gastric cancer patients.
5-year cumulative survival % (95% CI)
All patients UCHL5 negative UCHL5 positive p value
UCHL5 36.2 (31.7–40.7) 31.3 (22.5–40.4) 37.7 (32.5–42.8) 0.107
Age, years
<66 42.9 (36.3–49.4) 41.2 (27.4–54.5) 43.4 (35.9–50.7) 0.789
66 29.5 (23.6–35.6) 22.0 (11.8–34.2) 31.8 (24.9–38.9) 0.037
Gender
Male 35.1 (28.7–41.6) 30.7 (18.4–43.9) 36.4 (29.0–43.8) 0.300
Female 37.1 (30.9–43.3) 31.9 (20.0–44.5) 38.7 (31.6–45.8) 0.221
Laure´n classification
Intestinal 37.7 (30.7–44.7) 30.4 (15.1–47.3) 39.1 (31.4–46.8) 0.193
Diffuse 34.7 (28.9–40.6) 31.1 (20.7–42.0) 36.1 (29.2–43.0) 0.335
TNM stage
IA-IB 86.8 (77.8–92.3) 77.5 (50.4–91.0) 89.1 (79.3–94.4) 0.341
IIA-IIB 58.1 (46.5–68.0) 39.5 (17.9–60.5) 63.2 (49.9–73.9) 0.027
IIIA-IIIC 18.7 (12.9–25.3) 27.2 (14.3–41.9) 15.8 (9.8–23.2) 0.529
IV 4.2 (1.6–8.9) - 5.5 (2.0–11.5) 0.437
pT-classification
pT1 91.0 (81.0–95.9) 86.7 (56.4–96.5) 92.3 (80.7–97.0) 0.282
pT2 64.7 (51.7–75.1) 45.5 (19.6–68.3) 70.3 (55.5–81.0) 0.009
pT3 23.9 (17.8–30.5) 25.2 (12.5–40.0) 23.6 (16.8–31.0) 0.644
pT4 12.0 (7.2–18.1) 9.2 (2.5–21.6) 12.9 (7.2–20.3) 0.364
pN-classification
pN0 66.4 (58.4–73.2) 53.5 (34.9–68.9) 69.7 (60.9–77.0) 0.159
pN+ 20.2 (15.7–25.2) 22.6 (13.3–33.4) 19.5 (14.4–25.1) 0.783
Tumor size, cm
<5 64.6 (56.6–71.5) 45.5 (30.0–59.7) 71.4 (62.3–78.6) 0.001
5 19.7 (15.2–24.7) 19.0 (10.0–30.3) 19.9 (14.8–25.6) 0.479
Abbreviations: UCHL5 = ubiquitin C-terminal hydrolase L5, CI = confidence interval. Log rank-test is calculated for the entire follow up period (maximum 30 years).
https://doi.org/10.1371/journal.pone.0193125.t002
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19–9 markers suggest that they may be beneficial in the detection of recurrence, and they are
measured in clinical practice [29]. Though the patient number per subgroup in this patient
cohort is relatively small, statistical significance and considerable differences in survival
emerged. It is therefore conceivable that UCHL5 could have relevant prognostic potential,
especially in the context of more extensive patient cohorts.
Among the strengths of this study is a large patient cohort, with long clinical follow-up and
survival data. It is important to note, however, that with this TMA method, only a small sub-
section of the tumor is sampled and scored for immunoexpression. Conversely, though this
method may be somewhat crude, it allows processing of a large patient volume in a reasonable
time, and by a standardized staining method.
Table 3. Cox regression analysis for cancer-specific survival in gastric cancer.
Univariable survival analysis
Variable Hazard ratio 95% CI p value
Age, years
<66 1.00
66 1.48 1.18–1.86 0.001
Gender
Male 1.00
Female 0.98 0.79–1.23 0.893
TNM stage
IA-IB 1.00
IIA-IIB 4.12 2.24–7.60 <0.001
IIIA-IIIC 11.18 6.42–19.48 <0.001
IV 32.28 18.63–57.82 <0.001
pT classification
pT1 1.00
pT2 3.82 1.73–8.40 0.001
pT3 12.50 6.12–25.55 <0.001
pT4 19.21 9.37–39.42 <0.001
pN classification
pN0 1.00
pN+ 4.10 3.06–5.48 <0.001
pM classification
pM0 1.00
pM1 5.54 4.33–7.10 <0.001
Laure´n classification
Intestinal 1.00
Diffuse 1.10 0.87–1.38 0.438
Tumor size, cm
<5 1.00
5 3.80 2.86–5.05 <0.001
UCHL5
Negative 1.00
Positive 0.81 0.63–1.05 0.108
Abbreviations: UCHL5 = ubiquitin C-terminal hydrolase L5, CI = confidence interval.
https://doi.org/10.1371/journal.pone.0193125.t003
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